Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Migraine Clinical Trial

Official title:

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04845178
• Other study ID #: ABP-20001
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 1, 2021
• Est. completion date: September 5, 2024

Study information

• Verified date: December 2023
• Source: AEON Biopharma, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the Company's novel injection paradigm.

Description:

The Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose of ABP-450 group, a high dose of ABP-450 group, and a placebo group. All patients will receive two treatment cycles utilizing the Company's novel treatment paradigm involving fewer injections than the current botulinum toxin treatment option for chronic migraine.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 797
• Est. completion date: September 5, 2024
• Est. primary completion date: June 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient can understand the ICF, provides signed ICF and patient privacy information (eg, Authorization for Use and Release of Health and Research Study Information) before initiating any study-specific procedure, and agrees to comply with protocol requirements.

2. Male or female patients 18 years or older of age (no upper age limit) at the time of signing the informed consent.

3. Patient has at least a 1-year history of episodic migraine (with or without aura) or chronic migraine (with or without aura) according to the ICHD-3 (2018) definition and diagnostic criteria.

4. Age of the patient at the time of migraine onset <50 years.

5. History of, on average =6 migraine or probable migraine days per month in the 3 months prior to Screening.

6. Patient is on a stable dose of medications, if any, as recommended by the patient's health care practitioner, used for acute treatment of migraine for at least 3 months prior to Screening. Patient is not taking any migraine prophylactic treatment prohibited per protocol or if on prophylactic treatment has washed out.

7. A Woman of Child Bearing Potential (WOCBP) must be willing and able to use a medically acceptable and effective method of birth control as determined by the investigator, during the entire study.

8. A WOCBP must have a negative pregnancy test at Screening.

9. Patient is able to read, understand, and complete the eDiary.

10. Patient is willing and able to adhere to the study assessments, visit schedules, and prohibitions, as described in this protocol.

Exclusion Criteria:

Medical Conditions

1. History of migraine accompanied by diplopia or decreased level of consciousness, or retinal migraine.

2. Current diagnosis of chronic tension-type headache, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or cranial neuropathy.

3. Confounding and clinically significant pain syndromes (eg, fibromyalgia, chronic low back pain, complex regional pain syndromes) as evaluated by the investigator.

4. Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease that might interfere with the study.

5. Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to Screening as evaluated by the investigator. Patients with a lifetime history of psychosis, mania, or dementia are excluded.

6. History of addiction, including alcohol or drugs of abuse, within 6 months prior to Screening.

7. Hepatitis B (HBsAg positive) or hepatitis C (ie, detectable HCV RNA) virus infection.

Note: Patients with a prior history of treated hepatitis B virus infection who are antigen negative or patients with a prior history of treated HCV infection who are HCV RNA undetectable may be considered after consultation with the study medical monitor.

8. Any infection or clinically significant skin problem in any of the injection sites.

9. Have been injected with anesthesia or steroids in the targeted muscles during the 30 days immediately prior to initiation of the Baseline period.

10. Any medical condition (including but not limited to viral or other active infections) that, in the opinion of the investigator, classifies the patient as unsuitable for participation in the study or patients who do not seem to be in good general health at the time of Screening, and prior to any investigational study drug administration.

Note: Patients will not routinely be tested for COVID-19 during the study. Patients presenting with fever or who are symptomatic for COVID-19 will be required to be tested and treated through their general practitioner.

Other Diagnostic Assessments

11. Significant risk of self-harm based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator; patients must be excluded if they report suicidal ideation with intent, with or without a plan (ie, Type 4 or 5 on the C-SSRS) in the past 6 months or report suicidal behavior in the past 6 months prior to Screening.

12. Body mass index =38 kg/m2 at Screening.

Prior/Concomitant Medications and Treatments

13. Use of opioids or barbiturates >2 days per month in the 3 months prior to Screening.

14. Use of CBD or other types of cannabinoids in the 3 months prior to Screening and throughout the study.

15. Any use of botulinum toxin for migraine or any other medical reasons within 4 months prior to Screening and during the Screening and Baseline periods and at or above the shoulders at any time during the study.

16. Any monoclonal antibody CGRP inhibitor treatment (within or outside of a clinical study) within 6 months prior to Screening and throughout the study.

17. Any orally administered non-peptide CGRP antagonists (within or outside of a clinical study) within 4 weeks prior to the Baseline period and throughout the study.

18. Use of devices for the treatment of migraine (ie, non-invasive neuromodulation therapies including but not limited to non-invasive nerve stimulation [gammaCore], transcranial magnetic stimulation [Cefaly], external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation, and peripheral neuroelectrical stimulation) during Screening and throughout the study.

19. Any other treatments or therapies (eg, acupuncture in head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and dental splints for headache) to the head, neck, or shoulder regions during Screening and throughout the study that, in the opinion of the investigator, would interfere with the investigational study drug.

20. History of inadequate response to 3 classes of medications (which have different mechanisms of action) prescribed for the prevention of migraine, excluding CGRP therapies.

21. History of hypersensitivity to human serum albumin, sucrose, or botulinum toxin type A or a positive test for botulinum toxin type A antibody.

Prior/Concurrent Clinical Study Experience

22. Participation in another interventional study within 6 months prior to Screening and throughout the study.

23. Female patients planning on becoming pregnant during the course of the study and/or lactating/breastfeeding.

24. Patient has donated or lost a significant volume (>450 mL) of blood or plasma within 30 days of screening.

25. Patient is an employee or family member of the investigator, study site personnel, PPD, or AEON.

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Drug:
• ABP-450
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
• Placebo
0.9% sodium chloride, sterile, unpreserved, USP/PhEur

Locations

Country	Name	City	State
Australia	Grampians Health	Ballarat	Victoria
Australia	Emeritus Research	Camberwell	Victoria
Australia	Liverpool Hospital	Liverpool	New South Wales
Australia	Alfred Hospital	Melbourne	Victoria
Canada	True North Clinical Research	Halifax	Nova Scotia
Canada	Diex Recherche Québec	Québec
Canada	CARe Clinic	Red Deer	Alberta
Canada	Bluewater Clinical Research Group	Sarnia	Ontario
United States	Albuquerque Clinical Trials Inc	Albuquerque	New Mexico
United States	Dent Neurologic Institute	Amherst	New York
United States	NeuroTrials Research Inc. - Clinedge - PPDS	Atlanta	Georgia
United States	Northwest Clinical Research Center	Bellevue	Washington
United States	Hassman Research Institute - ClinEdge - PPDS	Berlin	New Jersey
United States	Boston Clinical Trials Inc	Boston	Massachusetts
United States	Dayton Center for Neurological Disorders	Centerville	Ohio
United States	Crescent City Headache and Neurology Center	Chalmette	Louisiana
United States	MDFirst Research	Chandler	Arizona
United States	WR-ClinSearch	Chattanooga	Tennessee
United States	Cedar Crosse Research Center	Chicago	Illinois
United States	Delta Waves LLC - Hunt - PPDS	Colorado Springs	Colorado
United States	Axiom Research LLC	Colton	California
United States	DCT - Baxter LLC dba Discovery Clinical Trials	Dallas	Texas
United States	META Medical Research Institute, LLC	Dayton	Ohio
United States	Centricity Research Dublin Multispecialty	Dublin	Ohio
United States	Quest Research Institute - Hunt - PPDS	Farmington Hills	Michigan
United States	Community Research of South Florida	Hialeah	Florida
United States	Henry Ford Allegiance Neurology	Jackson	Michigan
United States	Velocity Research San Diego	La Mesa	California
United States	Barrett Clinic, P.C. - Clinedge - PPDS	La Vista	Nebraska
United States	Sandhill Research, LLC	Lake Mary	Florida
United States	Canvas Clinical Research	Lake Worth	Florida
United States	Wake Research - CRCN, LLC	Las Vegas	Nevada
United States	Collaborative Neuroscience Research	Long Beach	California
United States	Los Angeles Headache Center	Los Angeles	California
United States	Drug Studies America, Inc	Marietta	Georgia
United States	Tandem Clinical Research	Marrero	Louisiana
United States	Velocity Clinical Research - Boise - ERN - PPDS	Meridian	Idaho
United States	BioMed Research Institute, INC	Miami	Florida
United States	Medical Research Center, LLC	Miami	Florida
United States	Bryant Research Group	Nashville	Tennessee
United States	The Orthopedic Foundation	New Albany	Ohio
United States	New York Neurology Associates	New York	New York
United States	Renstar Medical Research	Ocala	Florida
United States	Quality Clinical Research	Omaha	Nebraska
United States	Aspen Clinical Research LLC - Clinedge - PPDS	Orem	Utah
United States	Kansas Institute of Research, LLC	Overland Park	Kansas
United States	Innovation Medical Research Center	Palmetto Bay	Florida
United States	Thomas Jefferson University, Jefferson Headache Center	Philadelphia	Pennsylvania
United States	Arizona Neuroscience Research	Phoenix	Arizona
United States	Elite Clinical Studies, LLC	Phoenix	Arizona
United States	Preferred Primary Care Physicians	Pittsburgh	Pennsylvania
United States	Anderson Clinical Research	Redlands	California
United States	StudyMetrix Research, LLC	Saint Peters	Missouri
United States	Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS	San Diego	California
United States	Clinvest Research LLC	Springfield	Missouri
United States	New England Institute for Neurology and Headache	Stamford	Connecticut
United States	Mercury Clinical Research Incorporated	Sugar Land	Texas
United States	Clinical Research Consortium Arizona	Tempe	Arizona
United States	MedVadis Research	Waltham	Massachusetts
United States	Paradigm Clinical Research Centers	Wheat Ridge	Colorado
United States	Upstate Clinical Research Associates LLC	Williamsville	New York
United States	Clinical Research of Central Florida - ClinEdge - PPDS	Winter Haven	Florida

Sponsors (2)

Lead Sponsor	Collaborator
AEON Biopharma, Inc.	PPD

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Mean Change in Patient Global Impression of Change (PGI-C) Score	The Mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Other	Mean Change in Patient Global Impression of Severity (PGI-S) Score	The Mean change in the subject's assessment of the severity of their condition since the start of treatment measured by the Patients' Global Impression of Severity (PGI-S) Scale will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Other	Mean Change in MIgraine Disability Assessment Score (MIDAS) Total Score	The Mean Change in the Migraine Disability Assessment Scale (MIDAS) between Baseline and End of Treatment assessed by Treatment Group. MIDAS is a 5-item self-administered questionnaire. The 5 items sum to a total MIDAS score of 0 to 155. A higher score indicates greater headache-related disability (worse score).	Baseline to Week 28 - End of Study.
Other	Percentage of Patients with Reduction in the Physical Impairment Domaine Score of the Migraine Physical Function Impact Diary (MPFID)	Percentage of patients with a reduction from Baseline on Physical Impairment Domain Score measured by Migraine Physical Function Impact Diary (MPFID) assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Primary	Change in Monthly Migraine Days	The primary efficacy endpoint will be the change in mean Monthly Migraine Days (MMD) from the 4-week Baseline period to Weeks 21 to 24 Treatment period.	Baseline to Weeks 21 to 24 Treatment period.
Primary	Incidence of Treatment Emergent Adverse Events	The primary safety endpoint will be the incidence of TEAEs throughout the study when dosed with placebo, ABP-450 (low dose), or ABP-450 (high dose).	Baseline to Week 28 - End of Study.
Secondary	Percentage of Patients with Reduction in Mean Migraine Days (MMD)	Percentage of patients with a reduction from Baseline of = 50 percent, = 75 percent and 100% percent in average number of MMD will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Secondary	Mean change in Monthly Migraine Days (MMD)	Overall mean change from Baseline in the number of MMD will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Secondary	Mean change in Monthly Migraine Days (MMD) requiring medications for acute treatment of migraine or headaches	Overall mean change from Baseline in number of MMD requiring migraine specific medication and non-specific medications for the acute treatment of migraine or headache will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Secondary	Mean change in Headache Hours	Overall mean change from Baseline in headache (either moderate or severe) hours will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Secondary	Mean Change in Monthly Headache Days	Overall mean change from Baseline in monthly headache days will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Secondary	Mean change of Migraine-Specific-Quality of Life (MSQ) Domains	The Mean Change in Migraine-Specific-Quality of Life (MSQ), a 14-item assessment, with each item rated on a 6-point scale (ranging from "none of the time" to "all of the time") with higher scores indicating better quality of life will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Secondary	Percentage of Patients with Reduction in Migraine Physical Function Impact Diary (MPFID)	Percentage of patients with a reduction from Baseline in the impact on Migraine Physical Function Impact Diary (MPFID) will be assessed by Treatment Group.	Baseline to Week 28 - End of Study.
Secondary	Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)	Percentage of patients with Suicidal Ideation and Behaviors will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).	Baseline to Week 28 - End of Study.
Secondary	Development of Anti-Drug Antibodies (ADA) to ABP-450	Percentage of patients developing Anti-Drug Antibodies to ABP-450 antibodies (binding and if positive, neutralizing) will be assessed.	Baseline to Week 28 - End of Study.